AlphaMaven

Company Logo'

Venture Capital

BioHealth Capital Fund

BioHealth Capital Fund
Healing the World One Investment at a Time
Request More Information
Back

Venture Capital

BioHealth Innovation Newsletter - March 16, 2021

posted by BioHealth Capital Fund
4mos ago 399

To view the newsletter click here.

  • Marina Massingham, CEO, Aifred Health, & Laurent Waessa, Sr. Business Development Advisor, Québec Government Office in New York, Virtually Visit BioTalk
  • VIRTUAL SBIR and OTHER NON-DILUTIVE FUNDING SOURCES WORKSHOP with 1:1 PARTNERING – March 17-19, 2021 (2)
  • Digital Health Forum Presented by EAGB and BioHealth Innovation Registration, Thu, Mar 25, 2021 at 1:00 PM | Eventbrite
  • Top 10 U.S. Biopharma Clusters (BHCR number 4 but metrics improved over 2020)
  • Innovation Showcase - American College of Cardiology (April, 1)
  • After merger, College Park startup IonQ plans to go public with $2 billion valuation
  • VLP Therapeutics names seasoned biotech venture capitalist Miwa Toyoda as CBO | National News | kpvi.com
  • Novavax Says Its COVID-19 Vaccine is 96% Efficacious | Time
  • J&J plans to produce up to 3 billion doses of vaccine next year, United States News & Top Stories - The Straits Times
  • Leveraging Artificial Intelligence in Human Health (Rich Bendis will Facilitate)
  • Opinion | A Vaccine Maker’s Investment: Emergent BioSolutions Responds - The New York Times
  • SPAC Alexandria Agtech/Climate Innovation Acquisition files for a $250 million IPO | Nasdaq
  • Rockville-based Pediametrix receives $1M from National Science Foundation for R&D - Technical.ly DC
  • Researchers in a Virginia Lab Lay Groundwork for U.S.-Made Drugs - Bloomberg
  • Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer · BioBuzz
  • BioHealth Capital Region Women Making Waves in Venture Capital · BioBuzz
  • 5 Questions with Destinie Burgan, Upstream Supervisor of Manufacturing, Emergent BioSolutions · BioBuzz
  • Inova and University of Virginia School of Medicine open new campus | Headlines | insidenova.com
  • Innovation alliance unveils new name and strategic plan for Western Virginia | Business Local | roanoke.com

To view the newsletter click here.

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
You May Also Enjoy The Following Posts
First Quadrant Insights: Congressional Gridlock And The Market
4mos ago HedgeFund Global Diversified Macro Fund
Montgomery County, Maryland-based BeneVir Biopharm, Inc. To Be Acquired By Janssen Biotech, Inc. For Up To $1.04B
4mos ago VentureCapital BioHealth Capital Fund
BioSpace - Maravai LifeSciences Acquires MockV Solutions
4mos ago VentureCapital BioHealth Capital Fund
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.